{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-080562","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-07-06T11:00:40+00:00","discovered_at":"2026-07-06T11:05:00.292015+00:00","generated_at":"2026-07-06T11:05:10.503658+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00","bullets":["Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.","Charge expected to reduce both GAAP and non-GAAP diluted EPS by ~$1.00 in Q2 2026.","Q2 2026 results not finalized; subject to financial statement closing procedures.","Company does not forecast such IPR&D charges due to uncertainty of timing and magnitude."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-080562","json":"https://secwatch.observer/filing/0001104659-26-080562.json","markdown":"https://secwatch.observer/filing/0001104659-26-080562.md","text":"https://secwatch.observer/filing/0001104659-26-080562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/0001104659-26-080562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T11:05:10.503658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}